Evoke Pharma (EVOK) Tops Q2 EPS by 2c
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Forward Air (FWRD) Appoints Shawn Stewart as CEO
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Noble Financial Keeps Evoke Pharma (EVOK) at 'Hold' Following Q2 Numbers; Still Awaiting Development Plans
August 16, 2016 8:43 AM EDTNoble Financial affirms Evoke Pharma (Nasdaq: EVOK) with a Hold rating following Q2 results issued Monday night.
Analyst Nathan Cali noted the following on Tuesday:
Operational costs incrementally lower. August 15th, 2016, reported second quarter financial results; no revenues as expected; SG&A $802,655... MoreFBR Capital Reiterates Outperform on Evoke Pharma (EVOK) Following 2Q Report
August 16, 2016 8:42 AM EDTFBR Capital reiterated an Outperform rating and $9.00 price target on Evoke Pharma (NASDAQ: EVOK) following the company's 2Q earnings report. EVOK reported a 2Q16 net loss of $3.0 million, or ($0.41)/ share, versus estimates of a net loss of $3.4 million, or ($0.47)/share.
Analyst Vernon Bernardino commented, "On... More